Maria I New, MD Email Maria New
-
- Positions
- PROFESSOR | Pediatrics, Endocrinology - Adrenal Steroid Disorders
- PROFESSOR | Genetics and Genomic Sciences
-
- Language
- English
Dr. Maria New is a Professor in the Division of Pediatric Endocrinology and Diabetes in the Jack and Lucy Clark Department of Pediatrics at the Icahn School of Medicine at Mount Sinai and Mount Sinai Kravis Children's Hospital.
Research and Academic Inquiries: 212-241-7847
Clinical Appointments: 212-241-8210
Mailing Address: One Gustave L. Levy Place, Box 1198 New York, NY 10029
Other websites
www.newchf.org
www.marianew.com
http://rarediseasesnetwork.epi.usf.edu/rgsdc/index.htm
Clinical Focus
- Disorders of the Adrenal, Ovary and Testis
Education
BA, Cornell University
Language
English
The primary research emphasis is on genetic steroid disorders. We continue to study two monogenic disorders: 21-hydroxylase deficiency and-hydroxylase deficiency, emphasizing genotype/phenotype correlation and prenatal diagnosis and treatment. A more precise definition of salt-wasting Congenital Adrenal Hyperplasia owing to 21-hydroxylase deficiency is being developed, in which mineralocorticoid secretion is evaluated by salt-deprivation studies. For the first time, patients who were treated in fetal life are old enough to participate in long-term outcome studies.
These studies will establish the safety of prenatal treatment, as they will include medical and psychoendocrine (gender) evaluations. We have made worldwide collaborations to study mutations in the CYP21A2 gene and have preliminary data indicating that mutations have ethnic specificity. Mice with a deletion of the CYP21A2 gene are being bred for studies and vectors are prepared for studies of gene therapy. As we have the largest population with Apparent Mineralocorticoid Excess (AME) owing to 11B-HSD2 deficiency, a disease Dr. New discovered in 1977, we are conducting medical follow-up searching for end organ disease. We have discovered a new mild form of AME, in which the phenotype is not as severe as the cases first described and the mutations in the 11B-HSD2 gene are different. This mild form may prove to be an important basis for low renin hypertension, which constitutes 40% of essential hypertension.
As hypertension is the second highest cause of death, detecting a genetic basis would provide new treatment modalities and would serve as a significant public health measure. Microarray studies are being utilized to study three newly discovered diseases whose genetic basis is unknown: a) Familial Hyperaldosteronism II; b) resistance to all steroids; c) a disorder of sexual differentiation in which a 46,XY SRY positive female (whose ovaries are also SRY positive) has given birth to a 46,XY female. After 50 years at Cornell, the Dr. New and her team moved to Mount Sinai in 2004, where the research in steroid disorders including clinical, hormonal and molecular studies has prospered.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. New during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Eymann Allison Hunter Jones
- Florida International University
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Elsevier
- Springer Science+Business Media LLC
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.